YOUR SHIELD AGAINST PROGRESSION IN ADVANCED PROSTATE CANCER

Fight for what matters with RUBRACA

With RUBRACA by your side, you can defend against BRCA-mutated advanced prostate cancer¹*

*RUBRACA treats metastatic castration-resistant prostate cancer, or mCRPC, which is prostate cancer that has spread to other parts of the body (metastatic) and that no longer responds to testosterone-lowering medical or surgical treatment.

RUBRACA is designed to help you fight BRCA-mutated advanced prostate cancer, providing more flexibility and control over your treatment journey

RUBRACA is the only PARPi that demonstrated superior results compared to chemotherapy^1,2

RUBRACA is the ONLY PARP inhibitor (PARPi) that can be used alone, before OR after receiving chemotherapy, and after ANY androgen receptor pathway inhibitor (ARPI)^1,3-5†

^†Patients should also receive a type of medication called a gonadotropin-releasing hormone (GnRH) analog, or they should have undergone surgical removal of both testicles (a process called bilateral orchiectomy).

FIND OUT WHAT MAKES RUBRACA DIFFERENT

UNDERSTAND HOW RUBRACA WORKS

GET SUPPORT AS YOU NAVIGATE TREATMENT

DID YOU KNOW

Having a BRCA, or BReast CAncer, gene mutation means that you have inherited or acquired a gene that can put you at a higher risk for certain types of cancers, including prostate cancer⁶

~20% of men with advanced prostate cancer have a BRCA mutation⁷

Men who are of Ashkenazi Jewish descent or have a family history of certain cancers, like ovarian or breast, are more likely to have a BRCA gene mutation⁶

Men with a BRCA2 mutation are at higher risk for developing prostate cancer before age 80⁶

Genetic testing matters in advanced prostate cancer

PARP, poly (adenosine diphosphate-ribose) polymerase.

REFERENCES: 1. RUBRACA (rucaparib). Prescribing Information. pharmaand GmbH. 2025. 2. Fizazi K, Piulats JM, Reaume MN, et al. Rucaparib or physician’s choice in metastatic prostate cancer. N Engl J Med. 2023;388(8):719-732. 3. Lynparza (olaparib). Prescribing Information. AstraZeneca Pharmaceuticals LP. 2025.
4. Akeega (niraparib and abiraterone acetate). Prescribing Information. Janssen Biotech, Inc. 2024. 5. Talzenna (talazoparib). Prescribing Information. Pfizer Inc. 2025.
6. BRCA gene changes: cancer risk and genetic testing. National Cancer Institute. https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet 7. Lozano R, Castro E, Aragón IM, et al. Genetic aberrations
in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. Br J Cancer.
2021;124(3):552-563.

Tap for safety information

IMPORTANT SAFETY INFORMATION

What is RUBRACA^® (rucaparib) used for?

RUBRACA tablets are a prescription medicine used in adults for:

The treatment of castration-resistant prostate cancer (prostate cancer that no longer responds to medical or surgical treatment that lowers testosterone):
- That has spread to other parts of the body (metastatic), and
- Has a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene, and you have been treated with certain medicines for your cancer.
Your healthcare provider will perform a test to make sure RUBRACA is right for you.

It is not known if RUBRACA is safe and effective in children.

What Warnings should you know about RUBRACA?

RUBRACA tablets may cause serious side effects including: Bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with RUBRACA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with RUBRACA. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily. Symptoms of low blood cell counts are common during treatment with RUBRACA, but can be a sign of serious problems, including MDS or AML.

Before you take RUBRACA, tell your healthcare provider about all of your medical conditions, including if you are a male with a female partner who is pregnant or able to become pregnant, effective birth control should be used during treatment and for 3 months after the last dose of RUBRACA. Do not donate sperm during use and for 3 months after the last dose of RUBRACA.

What other important information should I know about RUBRACA?

Your healthcare provider will do blood tests before and every month during treatment with RUBRACA to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with RUBRACA until your blood cell counts improve.

Avoid spending time in sunlight while on RUBRACA since your skin may become more sensitive to the sun and may sunburn more easily. You should wear a hat and clothes that cover your skin and use sunscreen to help protect against sunburn if you have to be in the sunlight.

What are the side effects of RUBRACA?

The most common side effects of RUBRACA in people with prostate cancer include: tiredness or weakness, muscle and joint pain, nausea, decrease in hemoglobin (anemia), decreased appetite, changes in liver and kidney function tests, constipation, diarrhea, vomiting, low blood cell counts, shortness of breath, swelling in your legs and feet, dizziness, decreased weight, stomach area (abdominal) pain, changes in how food tastes, rash, tingling sensation and numbness, cough, headache, urinary tract infection, bleeding, photosensitivity reaction.

These are not all the possible side effects of RUBRACA. Call your healthcare provider for medical advice about side effects.

What other medications might interact with RUBRACA?

RUBRACA can increase the amounts of other medications you may be taking, which can increase the risk of side effects. Tell your healthcare provider about all your medical conditions and all medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to pharma& at 1-800-506-8501.

This information is not comprehensive.
- How to get more information:
  - Talk to your health care provider or pharmacist.
  - Visit www.rubracaprostate.com to obtain the FDA-approved product labeling.

Please see full Prescribing Information for RUBRACA.

YOUR SHIELD AGAINST PROGRESSION IN ADVANCED PROSTATE CANCER

Fight for what matters with RUBRACA

RUBRACA is designed to help you fight BRCA-mutated advanced prostate cancer, providing more flexibility and control over your treatment journey

RUBRACA is the only PARPi that demonstrated superior results compared to chemotherapy1,2

DID YOU KNOW

Having a BRCA, or BReast CAncer, gene mutation means that you have inherited or acquired a gene that can put you at a higher risk for certain types of cancers, including prostate cancer6

~20% of men with advanced prostate cancer have a BRCA mutation7

Men who are of Ashkenazi Jewish descent or have a family history of certain cancers, like ovarian or breast, are more likely to have a BRCA gene mutation6

Men with a BRCA2 mutation are at higher risk for developing prostate cancer before age 806

Genetic testing matters in advanced prostate cancer

IMPORTANT SAFETY INFORMATION

What is RUBRACA® (rucaparib) used for?

What Warnings should you know about RUBRACA?

YOU ARE NOW LEAVING RubracaProstate.com

Are you sure you want to leave?

RUBRACA is the only PARPi that demonstrated superior results compared to chemotherapy^1,2

Having a BRCA, or BReast CAncer, gene mutation means that you have inherited or acquired a gene that can put you at a higher risk for certain types of cancers, including prostate cancer⁶

~20% of men with advanced prostate cancer have a BRCA mutation⁷

Men who are of Ashkenazi Jewish descent or have a family history of certain cancers, like ovarian or breast, are more likely to have a BRCA gene mutation⁶

Men with a BRCA2 mutation are at higher risk for developing prostate cancer before age 80⁶

What is RUBRACA^® (rucaparib) used for?